glp-1 eating disorder Agonist for Binge Disorder: Evidence and Safety New hope for binge eating

Tirzepatide has shown similar results: in a phase 2 trial, up to 73.3% of participants at the highest dose achieved MASH resolution without worsening fibrosis at 52 weeks, compared to 13.2% on placebo

We also assessed whether patients with preexisting DR received treatment with agents targeting vascular endothelial growth factor (VEGF) or, more broadly, with intravitreal injections, laser panretinal photocoagulation, or retinal surgery via vitrectomy either individually or as a composite treatment outcome

These drugs not only aid in weight loss but also offer benefits in managing comorbid conditions such as cardiovascular diseases and type 2 diabetes

LIXIPARK, published in the New England Journal of Medicine in 2024, was the strongest result to date

7 The mean weight and BMI at baseline were 104.8 kg and 38.0 kg/m 2 , respectively, and after 72 weeks, the weight loss rates in patients who received tirzepatide at doses of 5 mg, 10 mg, and 15 mg were 15%, 19.5%, and 20.9%, respectively, which were significantly higher than the 3.1% weight loss rate observed in patients who received placebo